In tumor cells, especially those with an EMT phenotype, CD73 and some factors like TGFβ form a positive feedback loop in that TGFβ signaling increases CD73 expression and CD73 produces more eADO stimulating A2A and A2B receptor pathways to favor TGFβ production and secretion; thus, CD73/eADO receptor signaling contributes to EMT promotion in cancer cells (78). This evidence concerns the gene TGFB1 and cancer.